IV-275 is a dual inhibitor targeting the bromodomains of both BRG1 and BRM. This compound not only augments DNA damage when combined with Temozolomide and Bleomycin but also suppresses the invasiveness of GBM cells. Furthermore, IV-275 amplifies Temozolomide-induced cell death and its apoptosis-inducing activity [1].